Johnson & Johnson / Eisai / Cilag GmbH International / SuperGen Inc. / / /
Event
FDA Phase / /
IndustryTerm
cancer therapeutics / treatment of leukemia / marketed product / pharmaceutical / marketed products / /
MedicalCondition
leukemia / breast cancers / colon cancers / novel cancer / Stand Up to Cancer / high-risk myelodysplastic syndromes / acute myeloid leukemia / lung cancers / /
MedicalTreatment
cancer therapeutics / /
Organization
Stand Up to Cancer Epigenetics Dream Team / American Society of Hematology / /
Person
Susanna Chau / Mohammad Azab / Timothy L. Enns / / /
Position
Chief Medical Officer / Manager Investor Relations schau@supergen.com / Senior Vice President Corporate Communications & Business Development tenns@supergen.com / /
SuperGen Announces Enrollment of First Patient in First in Human Trial of SGI-110 in MDS and AML Patients DUBLIN, Calif., Jan 05, 2011 (BUSINESS WIRE) -SuperGen, Inc. (NASDAQ:SUPG) today announced that it has enrolled th